Quetiapine: dose-response relationship in schizophrenia

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Quetiapine is a common second-generation antipsychotic for schizophrenia and bipolar mania.
• A 'high-dose' theory suggests higher quetiapine dosages may be needed, leading prescribers to exceed licensed limits.
• This review examines data on quetiapine use in acute schizophrenia exacerbations.

Purpose of the Study:

• To review clinical and neuroimaging data on quetiapine dosage for acute schizophrenia.
• To evaluate the evidence supporting the 'high-dose' theory of quetiapine activity.

Main Methods:

• Review of fixed-dose efficacy studies of immediate-release (IR) and extended-release (XR) quetiapine.
• Analysis of effectiveness studies comparing quetiapine to other antipsychotics.
• Examination of case reports and neuroimaging data related to high-dose quetiapine use.

Main Results:

• Fixed-dose studies show IR quetiapine (150-450 mg/day) is effective and comparable to higher doses (600-750 mg/day).
• XR quetiapine (600-800 mg/day) showed similar efficacy, superior to 400 mg/day.
• Effectiveness studies indicate doses averaging 565-653 mg/day were less effective than some comparators.
• Evidence supporting doses >800 mg/day is limited to case reports and practice observations.

Conclusions:

• Robust controlled data support the standard quetiapine dosage range for schizophrenia treatment.
• The evidence does not substantiate the need for higher-than-licensed quetiapine dosages for full therapeutic effect.
• Further high-dose trials are needed to definitively confirm or refute the 'high-dose' hypothesis.